Eagle reaches settlement agreement with Dr. Reddy’s on Bendeka

Under the agreement, Dr. Reddy’s has the right to market its product beginning Nov. 17, 2027, or earlier based on certain circumstances.

Sandra Levy

4/12/2023

Eagle has reached a settlement agreement with Dr. Reddy’s.

Eagle had asserted its Orange Book-listed patents against Dr. Reddy’s related to its new drug application referencing Bendeka.

Bendeka is indicated for the treatment of patients with chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Under the settlement agreement, Dr. Reddy’s has the right to market its product beginning Nov. 17, 2027, or earlier based on certain circumstances.

The settlement with Dr. Reddy’s follows Eagle’s previously announced settlements with Hospira and Accord related to their new drug applications referencing Bendeka.

Related Topics